Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697301 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
A Phase 2 study of Advanced Melanoma, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 740
- Enrollment target
- 20
- Study locations
NCT06697301: Recruiting Phase 2 study of Advanced Melanoma, sponsored by Eikon Therapeutics.
NCT06697301 is a Phase 2 study of Advanced Melanoma that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 740 participants, above the 137-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (440% higher). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06697301, a Phase 2 study of Advanced Melanoma, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 740 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Primary Outcome
Progression-free survival (PFS) is defined as the time from the date of randomization to documented progressive disease per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG EIK1001
- DRUG Pembrolizumab (KEYTRUDA® )
Study Locations (20)
California
- Helios Clinical Research - Los Angeles
- Providence Medical Foundation - Santa Rosa
Missouri
- MidAmerica Cancer Care - Kansas City
- Washington University School of Medicine in St. Louis - St Louis
Arizona
- Ironwood Cancer & Research Centers - Chandler
Arkansas
- Genesis Cancer and Blood Institute - Hot Springs
Colorado
- UCHealth Memorial Hospital Central - Colorado Springs
Florida
- Bioresearch Partner - Hialeah
Maryland
- The Center for Cancer and Blood Disorders - Bethesda
Ohio
- Gabrail Cancer Center Research LLC - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2040-12 |
| Phase | Phase 2 |
What NCT06697301 shows while recruiting
NCT06697301 is an interventional study that assigns participants to a tested intervention. The registered 740 participants enrollment target is mid-sized for trials with a published cap, above the 137-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (440% higher).
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which EIK1001 is the first listed.
NCT06697301 names 20 study sites across 18 states, led by California, Missouri, Arizona.
Frequently Asked Questions
What is clinical trial NCT06697301 about?
NCT06697301 is a clinical study titled "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.". The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
What is the current status of trial NCT06697301?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 740 participants. The study started on 2025-05-22. Estimated completion is 2040-12.
What conditions does trial NCT06697301 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT06697301?
The interventions under investigation include: EIK1001 (DRUG), Pembrolizumab (KEYTRUDA® ) (DRUG).
Who is sponsoring clinical trial NCT06697301?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06697301 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06697301's enrollment target sits among peer trials
740 1st of 21 higher than 21 of 21 other Advanced Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
RECRUITING · Phase 2
-
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- NCT06172478 · 740 participants · Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI